Ronald Paquette, MD
Hematology & Oncology · Los Angeles, CANPI 1992725576
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,045 of the $24,693 with a category attached, or 81.2%. 19 manufacturers reported payments, led by Novartis at 49.4% of the total. 2025 is the largest year on record at $9,072, more than ten times the $580 reported in 2019.
Across 57 payments — averaging $433.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$12K
- Servier Pharmaceuticals LLC$6K
- AstraZeneca$5K
- Johnson & Johnson$386
- E.r. Squibb & Sons, L.L.C.$351
- Takeda Pharmaceuticals U.S.A., Inc.$246
- plus $1K from 13 others
Across 53 payments — averaging $3905.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$129K
- AstraZeneca$30K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Bristol Myers Squibb$14K
- Pharmacyclics LLC, An Abbvie Company$8K
- Incyte Corporation$7K
What the payments were for
- Consulting fees$20,04581%
- Travel & lodging$8844%
- Food & beverage$3,63815%
- Education$1261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $12,207 |
| Servier Pharmaceuticals LLC | 7 | $5,734 |
| AstraZeneca(2 entities) | 10 | $4,616 |
| Johnson & Johnson | 3 | $386 |
| E.r. Squibb & Sons, L.L.C. | 3 | $351 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $246 |
| Karyopharm Therapeutics Inc. | 1 | $159 |
| Bristol Myers Squibb | 1 | $140 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Seagen Inc. | 1 | $125 |
| Pfizer | 1 | $122 |
| Astellas Pharma US Inc | 1 | $119 |
| Rigel Pharmaceuticals, Inc. | 1 | $107 |
| AbbVie | 1 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Stemline Therapeutics Inc. | 1 | $34 |
| Incyte Corporation | 1 | $25 |
| Beigene USA, Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,693 in reported general payments places this provider in the 80th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 21 | $567,667 |
| JakafiRuxolitinib Phosphate | 43 | $556,776 |
| ScemblixAsciminib Hydrochloride | 25 | $527,371 |
| SprycelDasatinib | 18 | $310,931 |
| PomalystPomalidomide | 12 | $279,689 |
| TasignaNilotinib Hcl | 13 | $261,852 |
| ImbruvicaIbrutinib | 24 | $140,056 |
| VenclextaVenetoclax | 17 | $39,231 |
| Cyclosporine ModifiedCyclosporine, Modified | 30 | $2,729 |
| ValacyclovirValacyclovir Hcl | 25 | $1,479 |
| Acyclovir | 41 | $1,051 |
| Hydroxyurea | 31 | $651 |
| Gabapentin | 18 | $584 |
| Levofloxacin | 13 | $168 |
| Pantoprazole Sodium | 16 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix, Tasigna | $12,207 | $789,22338 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $351 | $590,61930 claims |
| Incyte CorporationJakafi | $25 | $556,77643 claims |
| AbbVieVenclexta | $106 | $39,23117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.